The Effect of Intravenous Tranexamic Acid in Percutaneous Renal Biopsy: A Single Center, Triple-blinded Randomized Controlled Trial

The Effect of Intravenous Tranexamic Acid in Percutaneous Renal Biopsy: A Single Center, Triple-blinded Randomized Controlled Trial - TRANEPSY study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019504

Enrollment

Registered

2015-11-16

Start date

2015-11-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Any conditions that are the indication of percutaneous renal biopsy

Interventions

Higher dose of tranexamic acid (TA): 1,000mg TA will be administered intravenously with the bolus dose of 500mg just before the renal biopsy, then administered intravenously with the continuous dose

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria will be adult patients who are aged 20 years or more, and who will undergo percutaneous biopsy of the native kidney.

Exclusion criteria

Exclusion criteria: Exclusion criteria will be patients who are suspected of amyloidosis, who have any contraindication of tranexamic acid, who are pregnant or breast-feeding, who need tranexamic acid for treatment or who are thought not to be suitable to participate in the study.

Design outcomes

Primary

Measure	Time frame
Perirenal hematoma measured by using ultrasonography on the next morning after percutaneous renal biopsy	—

Countries

Japan

Contacts

Public ContactJunichi Izawa

Kyoto University Department of Preventive Services, Kyoto University Graduate School of Public Health

jizawa13@gmail.com075-753-2426

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026